KR20220154796A - 변형된 안지오텐신-전환 효소 2 (ace2) 및 이의 용도 - Google Patents

변형된 안지오텐신-전환 효소 2 (ace2) 및 이의 용도 Download PDF

Info

Publication number
KR20220154796A
KR20220154796A KR1020227035927A KR20227035927A KR20220154796A KR 20220154796 A KR20220154796 A KR 20220154796A KR 1020227035927 A KR1020227035927 A KR 1020227035927A KR 20227035927 A KR20227035927 A KR 20227035927A KR 20220154796 A KR20220154796 A KR 20220154796A
Authority
KR
South Korea
Prior art keywords
leu
ace2
ser
asn
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227035927A
Other languages
English (en)
Korean (ko)
Inventor
에릭 프록코
아스랄 말릭
잘레스 러만
리앙휘 장
시친 시옹
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20220154796A publication Critical patent/KR20220154796A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485Exopeptidases (3.4.11-3.4.19)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023Angiotensin-converting enzyme 2 (3.4.17.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/165Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
KR1020227035927A 2020-03-16 2021-03-16 변형된 안지오텐신-전환 효소 2 (ace2) 및 이의 용도 Pending KR20220154796A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062989976P 2020-03-16 2020-03-16
US62/989,976 2020-03-16
US202063022151P 2020-05-08 2020-05-08
US63/022,151 2020-05-08
US202063042907P 2020-06-23 2020-06-23
US63/042,907 2020-06-23
US202063089895P 2020-10-09 2020-10-09
US63/089,895 2020-10-09
PCT/US2021/022611 WO2021188576A1 (en) 2020-03-16 2021-03-16 Modified angiotensin-converting enzyme 2 (ace2) and use thereof

Publications (1)

Publication Number Publication Date
KR20220154796A true KR20220154796A (ko) 2022-11-22

Family

ID=75439530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035927A Pending KR20220154796A (ko) 2020-03-16 2021-03-16 변형된 안지오텐신-전환 효소 2 (ace2) 및 이의 용도

Country Status (8)

Country Link
US (1) US20230193235A1 (https=)
EP (1) EP4121170A1 (https=)
JP (1) JP2023518038A (https=)
KR (1) KR20220154796A (https=)
AU (1) AU2021239879A1 (https=)
BR (1) BR112022018527A2 (https=)
CA (1) CA3174683A1 (https=)
WO (1) WO2021188576A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263019A1 (ko) * 2023-06-20 2024-12-26 주식회사 엔큐라젠 Sars-cov-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057176A (zh) * 2020-03-21 2023-05-02 赖瑞克斯生物科技公司 Ace2和补体途径的双特异性和三特异性功能分子及其用途
EP3884957A1 (en) * 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
IL276627A (en) * 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
CN117120621A (zh) * 2020-11-12 2023-11-24 上海科技大学 提高效率和准确性的基因组编辑
JP2024540722A (ja) * 2021-11-01 2024-11-01 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 変異型アンジオテンシン変換酵素2(ace2)を含む組換え/融合ポリペプチド
WO2023081958A1 (en) * 2021-11-11 2023-05-19 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antiviral agent comprising a cellular entry receptor and fc region component
CN114606219B (zh) * 2022-04-01 2023-10-31 北京大学 一种冠状病毒中和效应蛋白及其应用
EP4507787A1 (en) * 2022-04-13 2025-02-19 Paradigm Immunotherapeutics, Inc. Methods of preventing or treating infection by respiratory viruses including sars-cov-2
CN117304317B (zh) * 2022-06-28 2024-08-02 四川大学 Ace2受体特异性结合肽及其应用
EP4386084A1 (en) * 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
WO2024215776A1 (en) * 2023-04-10 2024-10-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Recombinant ace2 polypeptide and uses thereof
CN117447609A (zh) * 2023-10-25 2024-01-26 山西锦波生物医药股份有限公司 灭活冠状病毒的融合蛋白及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1515752E (pt) * 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
AU2013216910A1 (en) * 2012-02-10 2014-08-28 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263019A1 (ko) * 2023-06-20 2024-12-26 주식회사 엔큐라젠 Sars-cov-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
EP4121170A1 (en) 2023-01-25
JP2023518038A (ja) 2023-04-27
AU2021239879A1 (en) 2022-09-29
WO2021188576A1 (en) 2021-09-23
US20230193235A1 (en) 2023-06-22
CA3174683A1 (en) 2021-09-23
BR112022018527A2 (pt) 2022-10-25

Similar Documents

Publication Publication Date Title
KR20220154796A (ko) 변형된 안지오텐신-전환 효소 2 (ace2) 및 이의 용도
Procko The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2
US20230257726A1 (en) Ace2 compositions and methods
US11466062B2 (en) Ankyrin repeat binding proteins and their uses
York et al. A novel zinc-binding domain is essential for formation of the functional Junin virus envelope glycoprotein complex
WO2022064494A2 (en) Methods and compositions for treating coronaviral infections
WO2022058591A2 (en) Sars-cov-2-nanobodies
US20100261640A1 (en) Soluble and membrane anchored forms of lassa virus subunit proteins
CN119998313A (zh) 沙贝病毒刺突蛋白s2亚基结合剂
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
JP2026010683A (ja) 呼吸器合胞体ウイルスのmRNAワクチン及びその調製方法と使用
EP3561056B1 (en) Peptide for treating age-related macular degeneration
JP2025512512A (ja) コロナウイルス感染症の予防又は治療のための組成物
CN114891075A (zh) 一种对新冠病毒s蛋白rbmfp结构域具有结合亲和力的多肽及其应用
US20170198014A1 (en) Polypeptides and their use for treating influenza
Liu et al. F1 ATP synthase β subunit is a putative receptor involved in white spot syndrome virus infection in shrimp by binding with viral envelope proteins VP51B and VP150
EA048858B1 (ru) Модифицированный ангиотензинпревращающий фермент 2 и его применение
CN116601291A (zh) 修饰的血管紧张素转换酶2(ace2)及其用途
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
Werner Identification of lead molecules for the development of antivirals targeting the Ebola virus matrix protein VP40
US20250145692A1 (en) Chimera molecules for sars-cov-2 and methods of use
US20250277003A1 (en) Glycosylated rbd and use thereof
RU2788083C2 (ru) Пептид для лечения возрастной макулярной дегенерации
WO2025090946A1 (en) Compositions and methods for treating or preventing viral infection or for making a cell susceptible to viral infection or cell fusion
Blachier et al. Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application